TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03236311
Drug: 82Rubidium
Normalized name: rubidium
DrugBank: Rubidium (DB11346)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study: NCT03719898
Drug: Brigatinib
Normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brigatininb is administered in tablet form. It is to be taken until disease progression, unacceptable toxicity or completion of 24 cycles. patients may continue to take brigatininb beyond 24 cycles if they are benefiting from the drug
Study: NCT04003012
Drug: EMLA
Normalized name: EMLA
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (lidocaine 2.5% and prilocaine 2.5%)
Study: NCT04003012
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine 1%
Study: NCT04012931
Drug: Rilpivirine
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rilpivirine 25 mg tablets for the 25 mg daily dose, or tablets for or a weight-adjusted dose. Administered orally once daily.
Study: NCT02900443
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04388878
Drug: PF-07054894
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral ascending doses
Study: NCT04011410
Drug: Hydroxychloroquine Sulfate 200Mg Tab
Normalized name: HYDROXYCHLOROQUINE SULFATE 200MG TAB
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice daily for 90-days, administered two weeks prior to radiation/surgery of oligometastatic lesions
Study: NCT00287963
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00287963
Drug: vinorelbine tartrate
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01817985
Drug: GS-5816
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01517854
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg Revatio (sildenafil citrate) three times a day
Study: NCT02304211
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin will be administered either into the radial artery (microdose intervention) or IV (systemic intervention).
Study: NCT04261166
Drug: A1
Normalized name: CA1P
DrugBank: OXI-4503 (DB05143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Cannabis oil diluted in Olive oil. CBD 36.6 mg, THC 1.8 mg (6 drops)
Study: NCT04261166
Drug: A2
Normalized name: GA2
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medical Cannabis oil diluted in Olive oil. CBD 0.6 mg, THC 3.1 mg (1 drop)
Study: NCT03851250
Drug: MRx-4DP0004
Normalized name: MRx-4DP0004
DrugBank: MRx-4DP0004 (DB15751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomised to receive MRx-4DP0004 will take it in addition to their regular asthma medication.
Study: NCT01206062
Drug: Intensive control of SBP
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in the Intensive arm have a goal of SBP \<120 mm Hg. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics~Combination products will be available, depending on cost, utility, or donations from pharmaceutical companies.
Study: NCT03848143
Drug: onabotulinum toxin A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
Study: NCT03040596
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: fluticasone inhaler 44mcg/puff, 2 puffs twice a day for 4 weeks
Study: NCT03784547
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: already described
Study: NCT04261166
Drug: A3
Normalized name: PA3-17
DrugBank: PA3-17 (DB18569)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Cannabis oil diluted in Olive oil. CBD 3.1 mg. THC 3.1 mg (1 drop)
Study: NCT04261166
Drug: A4
Normalized name: CA4
DrugBank: Combretastatin A4 (DB14680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Cannabis (oil diluted in MCT oil). CBD 34.8 mg, THC 1.7 mg (6 drops)
Study: NCT04261166
Drug: B1
Normalized name: KB109
DrugBank: KB109 (DB16531)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablets. CBD 40 mg, THC 2 mg (1 tablet)
Study: NCT04261166
Drug: B2
Normalized name: B27PD
DrugBank: B27PD (DB16289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablets. CBD 30 mg, THC 5 mg (1 tablet)
Study: NCT04261166
Drug: B3
Normalized name: KB3305
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablets. CBD 40 mg (1 tablet)
Study: NCT01140581
Drug: DRONEDARONE
Normalized name: Dronedarone
DrugBank: Dronedarone (DB04855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg
Study: NCT04261166
Drug: B4
Normalized name: LTB4
DrugBank: Leukotriene B4 (DB12961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual tablets. CBD 40 mg (1 tablet)
Study: NCT01692717
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg
Study: NCT03190005
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)
Study: NCT02566928
Drug: 2% mupirocin ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of mupirocin ointment to the anterior nares with a sterile cotton applicator for five days.
Study: NCT01097577
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 capsule (75 mg) by mouth twice daily starting two hours prior to surgery and continuing 4 days postoperatively.
Study: NCT01366547
Drug: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
Study: NCT01366547
Drug: Dolutegravir 50 mg
Normalized name: dolutegravir 50 MG
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
Study: NCT01366547
Drug: abacavir 600 mg/lamivudine 300 mg
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
Study: NCT04298918
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive oral venetoclax.
Study: NCT04298918
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive intravenous (IV) trastuzumab emtansine.
Study: NCT03235739
Drug: Naloxegol 25 MG
Normalized name: naloxegol 25 MG
DrugBank: Naloxegol (DB09049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Naloxegol 25 MG
Study: NCT00128856
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00128856
Drug: Adriamycine
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00128856
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02960828
Drug: intravitreal Anti-VEGF injection
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year.
Study: NCT01066143
Drug: Seroquel XR
Normalized name: Seroquel XR
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Seroquel XR tablets will be flexibly dosed and begun at a target dose of 50 mg on day 1, 100 mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal daily dose of 400 mg on subsequent days.
Study: NCT02064530
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21 ml 0.5 %bupivacaine is applied interfasially
Study: NCT02064530
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied interfasially
Study: NCT02064530
Drug: serum physiologic
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 ml serum physiologic is applied interfasially
Study: NCT03006705
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Study: NCT03006705
Drug: Tegafur-gimeracil-oteracil potassium
Normalized name: tegafur
DrugBank: Oteracil (DB03209)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
Study: NCT03006705
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
Study: NCT02982356
Drug: Potassium Chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02632344
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg will be administered as a 30 minute IV infusion every 3 weeks on day 1 of each cycle after all procedures/assessments have been completed.
Study: NCT00006682
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 70mg/m2 on day 1 of every 21-day cycle
Study: NCT00006682
Drug: vinorelbine ditartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Navelbine 20mg/m2 on Day 1 and D8 of a 21-day cycle
Study: NCT00467896
Drug: Iloprost PD-6
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Period I: Patients received iloprost administered using PD-6 for the 37 days prior to the first dosing of iloprost using PD-15. Iloprost inhalation solution was delivered using the I-neb® AAD System. Patients were required to use their own I-neb®.
Study: NCT05288400
Drug: Norvasc 5mg tablet
Normalized name: Norvasc 5mg Tablet
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norvasc (amlodipine) 5mg, 1 tablet/day
Study: NCT05288400
Drug: Concor 5mg tablet
Normalized name: Loncor
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concor (bisoprolol fumarate) 5mg, 1 tablet/day
Study: NCT05288400
Drug: Coversyl 5mg tablet
Normalized name: Ioversol
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coversyl (perindopril arginine) 5mg, 1 tablet/day
Study: NCT00467896
Drug: Iloprost PD-15
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Period II: Iloprost inhalation solution was delivered using the investigational product PD-15 with I-neb® AAD System for 37 days. Patients were required to use their own I-neb®.
Study: NCT02847650
Drug: PF-06649751
Normalized name: PF-06649751
DrugBank: Tavapadon (DB14899)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02562378
Drug: Trastuzumab and non-pegylated liposomal doxorubicin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 Cohorts (3+3 design):~Cohort 1- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2) IV~Cohort 2- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (50 mg/m2) IV~Cohort 3- Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (60 mg/m2) IV
Study: NCT04503603
Drug: Lanadelumab
Normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive lanadelumab 300 mg IV infusion on Day 1 followed by Day 4.
Study: NCT01124175
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg Tablets
Study: NCT00000294
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03057106
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MEDI4736
Study: NCT03057106
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab
Study: NCT03057106
Drug: Platinum-Based Drug
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed, cisplatin, carboplatin or gemcitibine
Study: NCT03448068
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine 0.3 mg/kg (IBW) bolus with induction. Ketamine infusion 0.2mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion not titrated.
Study: NCT02711449
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125 mg methylprednisolone as an intravenously bolus injection approximately 30 minutes prior to skin incision.
Study: NCT00825500
Drug: Inhaled Loxapine 1.25 mg
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled Staccato Loxapine 1.25 mg, single dose
Study: NCT00825500
Drug: Inhaled Loxapine 2.5 mg
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled Staccato Loxapine 1.25 mg, single dose
Study: NCT00621699
Drug: 1 tablet Ezetrol(R) + 1 capsules Prograf(R)
Normalized name: (R)-LACOSAMIDE 1
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg Tacrolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
Study: NCT01528111
Drug: LX7101 (0.25%)
DrugBank: LX-7101 (DB16009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 0.25% LX7101
Study: NCT03844984
Drug: ketamine full dose
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group will receive induction of anesthesia using Ketamine 1 mg/Kg.
Study: NCT03844984
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This group will receive midazolam 0.05 mg/Kg
Study: NCT03844984
Drug: ketamine half dose
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg.
Study: NCT03844984
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group will receive lidocaince 1 mg/Kg diluted in 10 mL normal saline.
Study: NCT02940535
Drug: Diphereline (Triptorelin embonate)
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02940535
Drug: Decapeptyl (Triptorelin)
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02940535
Drug: human menopausal gonadotropin
Normalized name: Human menopausal gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02940535
Drug: human chorionic gonadotropin
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02605187
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 600mg po one time within 1 hour of delivery
Study: NCT02605187
Drug: Morphine (low)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal morphine dose 50mcg
Study: NCT02605187
Drug: Morphine (med)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal morphine dose 150mcg
Study: NCT02605187
Drug: Morphine (high)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal morphine 300mcg
Study: NCT02159729
Drug: ATX-101 (1 mg/cm^2)
Normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Study: NCT02159729
Drug: ATX-101 (2 mg/cm^2)
Normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Study: NCT02159729
Drug: ATX-101 (4 mg/cm^2)
Normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Study: NCT01358344
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg delayed-release tablet administered orally in the morning of Days 1-7
Study: NCT01358344
Drug: SCH 530348 (high percentage)
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg tablet containing \~46% active pharmaceutical ingredient (API) as free base (46+5%) administered orally on the morning of Day 5
Study: NCT01358344
Drug: SCH 530348 (standard percentage)
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg tablet containing \~23% API as free base (STANDARD) administered orally on the morning of Day 5
Study: NCT01344291
Drug: Curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin is prescribed to new cases of hyperprolactinoma
Study: NCT02325960
Drug: exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.
Study: NCT02325960
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ≥8 IU QD, and titrate based on a dosing algorithm targeting FPG \<6.1 mmol/L. Titration is only allowed in first 4 weeks.
Study: NCT00875030
Drug: artesunate sachets
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: single dose 50 mg (2 X 25 mg) artesunate sachets
Study: NCT00834522
Drug: Granisetron hydrochloride 1 mg tablets
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 1 mg, single dose non-fasting
Study: NCT02738970
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive a single dose of trastuzumab 600 mg SC separately, co-mixed or co-formulated with pertuzumab.
Study: NCT02738970
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive pertuzumab as a single agent injection, co-mixed or formulated as FDC with trastuzumab depending upon cohort. The dose will range from 400 to 1200 mg.
Study: NCT00905346
Drug: Topiramate 25 mg Capsules
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate Capsules 2 x 25 mg
Study: NCT02735395
Drug: Metronidazole 250 (7 days)
Normalized name: metronidazole 250 MG
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will intake Metronidazole 250 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
Study: NCT02735395
Drug: Metronidazole 400 (7 days)
Normalized name: metronidazole 400 MG
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will intake Metronidazole 400 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
Study: NCT02735395
Drug: Metronidazole 250 (14 days)
Normalized name: metronidazole 250 MG
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will intake Metronidazole 250 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
Study: NCT02735395
Drug: Metronidazole 400 (14 days)
Normalized name: metronidazole 400 MG
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will intake Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
Study: NCT02735395
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will intake Amoxicillin 500 mg. for 14 days, starting immediately after and the first session of Scaling and Root Planing.
Study: NCT00197639
Drug: Ritonavir-boosted indinavir
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no